Business Sentiment Survey

Shoppers are silhouetted as they stand near a sign advertising a sale at a shopping mall in Mumbai February 11, 2013. REUTERS/Vivek Prakash/Files

Asian businesses optimistic; sentiment in India falls

Asia's top companies have become more optimistic about their business outlook with the retail and shipping industries rebounding sharply in the second quarter of 2013, the latest Thomson Reuters/INSEAD Asia Business Sentiment Survey shows.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Asian Stocks Outlook

Asian Stocks Outlook

Asian stocks to lead the way to year's end, Fed seen pulling back - Reuters Poll.  Full Article 

Sensex @ 21,000?

Sensex @ 21,000?

Sensex to touch 21,000 by year end: Reuters poll.  Full Article 

Trade Reforms

Trade Reforms

U.S. groups form alliance to push for Indian trade reforms.  Full Article 

Options Before Fed

Options Before Fed

Fed seen keeping options open on pace of bond buying.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Advertising Milestone

Advertising Milestone

Exclusive - Facebook reaches 1 million active advertisers.  Full Article 

Reviving Infra

Reviving Infra

Road building revival offers rare hope for India infrastructure overhaul.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Citi resumes coverage on Sun Pharma with a 'buy' rating

Related Topics

Stocks

   
A man holds an umbrella to shield himself from the rain on a beach in Mumbai June 13, 2013. REUTERS/Danish Siddiqui

The rains are here

Monsoon rains have covered India ahead of the usual date.  Slideshow 

» Click here for more slideshows

Thu Feb 21, 2013 3:26pm IST

Reuters Market Eye - Citigroup resumes coverage of Sun Pharmaceutical Industries Ltd(SUN.NS) with a "buy" rating and a target price of 970 rupees.

Citi says Sun Pharma "stands out" in the sector due a "superior" business mix, with around 80 percent of its revenue coming from the United States and India, and growing fast in the rest of the world.

The investment bank also notes Sun's "excellent" track record on financial metrics, and expects growth to stay "strong" and premium valuations to sustain.

Sun shares were down 0.3 percent as of 3.26 pm, outperforming a 1.5 percent fall in the Nifty.

(Reporting by Abhishek Vishnoi)
Business
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.